Download PDF
CC BY 4.0 · Surg J (N Y) 2021; 07(03): e142-e146
DOI: 10.1055/s-0041-1731427
Case Report

Gastric Neuroendocrine Tumor

Naresh Kargwal
1   Department of General Surgery, Maulana Azad Medical College, New Delhi, India
,
Viraj Panda
1   Department of General Surgery, Maulana Azad Medical College, New Delhi, India
,
Abhijeet Jha
1   Department of General Surgery, Maulana Azad Medical College, New Delhi, India
,
Chandra Bhushan Singh
1   Department of General Surgery, Maulana Azad Medical College, New Delhi, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Gastric neuroendocrine tumor (gNET) is a rare carcinoid of the stomach whose incidence is increasing due to widespread use of upper gastrointestinal endoscopy (UGIE). There are four types of gNETs with different management strategies and prognosis. Here, we present a patient who came with abdomen pain and intermittent melena. UGIE showed a sessile polyp in the stomach. The patient subsequently underwent polypectomy and was symptomatically relieved.

Keywords

carcinoid - neuroendocrine - tumor - gastric

Ethics Approval and Consent to Participate

Not applicable.


Consent for Publication

Not applicable.


Availability of Data and Materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.




Publication History

Received: 11 December 2020

Accepted: 31 March 2021

Article published online:
19 July 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Kwon DH, Nakakura EK, Bergsland EK, Dai SC. Gastric neuroendocrine tumors: management and challenges. Gastrointestinal Cancer: Targets and Therapy 2017; 29 (07) 31-37
    CrossrefPubMedGoogle Scholar
  • 2 Dias AR, Azevedo BC, Alban LBV. et al. Gastric neuroendocrine tumor: review and update. Arq Bras Cir Dig 2017; 30 (02) 150-154
    CrossrefPubMedGoogle Scholar
  • 3 Lupinacci RM, Dias AR, Mello ES, Kondo A. Minute type I gastric carcinoid with regional lymph node metastasis. Int J Surg Pathol 2013; 21 (02) 169-172
    CrossrefPubMedGoogle Scholar
  • 4 Fossmark R, Sørdal Ø, Jianu CS. et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 2012; 36 (11-12): 1067-1075
    CrossrefPubMedGoogle Scholar
  • 5 Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract 2012; 2012: 287825
    CrossrefPubMedGoogle Scholar
  • 6 Carmack SW, Genta RM, Schuler CM, Saboorian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol 2009; 104 (06) 1524-1532
    CrossrefPubMedGoogle Scholar
  • 7 Li TT, Qiu F, Qian ZR, Wan J, Qi XK, Wu BY. Classification, clinicopathologic features, and treatment of gastric neuroendocrine tumors. World J Gastroenterol 2014; 20 (01) 118-125
    CrossrefPubMedGoogle Scholar
  • 8 Namikawa T, Oki T, Kitagawa H, Okabayashi T, Kobayashi M, Hanazaki K. Neuroendocrine carcinoma of the stomach: clinicopathological and immunohistochemical evaluation. Med Mol Morphol 2013; 46 (01) 34-40
    CrossrefPubMedGoogle Scholar
  • 9 Gonzalez HH, Acosta M, Yazji G, Bromer MQ. Type 1 gastric neuroendocrine tumor found on endoscopic polypectomy. Cureus 2019; 11 (03) e4193
    PubMedGoogle Scholar
  • 10 Grozinsky-Glasberg S, Kaltsas G, Gur C. et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008; 159 (04) 475-482
    CrossrefPubMedGoogle Scholar
  • 11 Gupta S, Johnson MM, Murthy R. et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104 (08) 1590-1602
    CrossrefPubMedGoogle Scholar
  • 12 Breeman WA, de Jong M, Kwekkeboom DJ. et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations, and future perspectives. Eur J Nucl Med 2001; 28 (09) 1421-1429
    CrossrefPubMedGoogle Scholar